NATERA INC (NTRA) Fundamental Analysis & Valuation
NASDAQ:NTRA • US6323071042
Current stock price
195.28 USD
-7.45 (-3.67%)
At close:
195.28 USD
0 (0%)
After Hours:
This NTRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NTRA Profitability Analysis
1.1 Basic Checks
- NTRA had negative earnings in the past year.
- In the past year NTRA had a positive cash flow from operations.
- In the past 5 years NTRA always reported negative net income.
- The reported operating cash flow has been mixed in the past 5 years: NTRA reported negative operating cash flow in multiple years.
1.2 Ratios
- NTRA has a better Return On Assets (-8.68%) than 83.30% of its industry peers.
- NTRA has a Return On Equity of -12.16%. This is amongst the best in the industry. NTRA outperforms 85.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.68% | ||
| ROE | -12.16% | ||
| ROIC | N/A |
ROA(3y)-16.77%
ROA(5y)-25.55%
ROE(3y)-28.3%
ROE(5y)-46.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NTRA's Gross Margin of 64.75% is fine compared to the rest of the industry. NTRA outperforms 79.08% of its industry peers.
- NTRA's Gross Margin has improved in the last couple of years.
- NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.42%
GM growth 5Y6.2%
2. NTRA Health Analysis
2.1 Basic Checks
- NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for NTRA has been increased compared to 1 year ago.
- Compared to 5 years ago, NTRA has more shares outstanding
- NTRA has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 23.65 indicates that NTRA is not in any danger for bankruptcy at the moment.
- NTRA has a better Altman-Z score (23.65) than 90.79% of its industry peers.
- The Debt to FCF ratio of NTRA is 1.06, which is an excellent value as it means it would take NTRA, only 1.06 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of NTRA (1.06) is better than 94.24% of its industry peers.
- NTRA has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
- NTRA has a Debt to Equity ratio (0.05) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 1.06 | ||
| Altman-Z | 23.65 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
- NTRA has a Current Ratio of 3.39. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of NTRA (3.39) is comparable to the rest of the industry.
- A Quick Ratio of 3.24 indicates that NTRA has no problem at all paying its short term obligations.
- NTRA has a worse Quick ratio (3.24) than 60.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.39 | ||
| Quick Ratio | 3.24 |
3. NTRA Growth Analysis
3.1 Past
- NTRA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.65%.
- The Revenue has grown by 35.90% in the past year. This is a very strong growth!
- Measured over the past years, NTRA shows a very strong growth in Revenue. The Revenue has been growing by 42.61% on average per year.
EPS 1Y (TTM)0.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.8%
Revenue 1Y (TTM)35.9%
Revenue growth 3Y41.14%
Revenue growth 5Y42.61%
Sales Q2Q%39.78%
3.2 Future
- The Earnings Per Share is expected to grow by 37.27% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 17.55% on average over the next years. This is quite good.
EPS Next Y-25.06%
EPS Next 2Y32.85%
EPS Next 3Y40.11%
EPS Next 5Y37.27%
Revenue Next Year19.68%
Revenue Next 2Y19.84%
Revenue Next 3Y19.71%
Revenue Next 5Y17.55%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. NTRA Valuation Analysis
4.1 Price/Earnings Ratio
- NTRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year NTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of NTRA indicates a rather cheap valuation: NTRA is cheaper than 89.44% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 363.63 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as NTRA's earnings are expected to grow with 40.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.85%
EPS Next 3Y40.11%
5. NTRA Dividend Analysis
5.1 Amount
- NTRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NTRA Fundamentals: All Metrics, Ratios and Statistics
195.28
-7.45 (-3.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2026-02-26/amc
Earnings (Next)05-06 2026-05-06/amc
Inst Owners93.51%
Inst Owner Change0.51%
Ins Owners3.04%
Ins Owner Change0.81%
Market Cap27.68B
Revenue(TTM)2.31B
Net Income(TTM)-208.16M
Analysts85
Price Target262.39 (34.37%)
Short Float %2.2%
Short Ratio2.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)50.47%
Min EPS beat(2)-68.19%
Max EPS beat(2)169.13%
EPS beat(4)2
Avg EPS beat(4)26.55%
Min EPS beat(4)-68.19%
Max EPS beat(4)169.13%
EPS beat(8)5
Avg EPS beat(8)29.82%
EPS beat(12)8
Avg EPS beat(12)21.96%
EPS beat(16)12
Avg EPS beat(16)18.12%
Revenue beat(2)2
Avg Revenue beat(2)11.68%
Min Revenue beat(2)10.13%
Max Revenue beat(2)13.23%
Revenue beat(4)4
Avg Revenue beat(4)11.53%
Min Revenue beat(4)10.13%
Max Revenue beat(4)13.23%
Revenue beat(8)8
Avg Revenue beat(8)13.31%
Revenue beat(12)12
Avg Revenue beat(12)10.39%
Revenue beat(16)14
Avg Revenue beat(16)8.14%
PT rev (1m)0.53%
PT rev (3m)10.6%
EPS NQ rev (1m)-0.53%
EPS NQ rev (3m)-4.57%
EPS NY rev (1m)1.17%
EPS NY rev (3m)-4.26%
Revenue NQ rev (1m)1.6%
Revenue NQ rev (3m)2.15%
Revenue NY rev (1m)2.71%
Revenue NY rev (3m)3.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 12 | ||
| P/FCF | 363.63 | ||
| P/OCF | 128.55 | ||
| P/B | 16.16 | ||
| P/tB | 23.11 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.52
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)0.54
FCFY0.28%
OCF(TTM)1.52
OCFY0.78%
SpS16.27
BVpS12.08
TBVpS8.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.68% | ||
| ROE | -12.16% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.75% | ||
| FCFM | 3.3% |
ROA(3y)-16.77%
ROA(5y)-25.55%
ROE(3y)-28.3%
ROE(5y)-46.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.42%
GM growth 5Y6.2%
F-Score5
Asset Turnover0.96
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 1.06 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 320.09% | ||
| Cap/Sales | 6.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.39 | ||
| Quick Ratio | 3.24 | ||
| Altman-Z | 23.65 |
F-Score5
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)243.71%
Cap/Depr(5y)291.51%
Cap/Sales(3y)4.73%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.8%
EPS Next Y-25.06%
EPS Next 2Y32.85%
EPS Next 3Y40.11%
EPS Next 5Y37.27%
Revenue 1Y (TTM)35.9%
Revenue growth 3Y41.14%
Revenue growth 5Y42.61%
Sales Q2Q%39.78%
Revenue Next Year19.68%
Revenue Next 2Y19.84%
Revenue Next 3Y19.71%
Revenue Next 5Y17.55%
EBIT growth 1Y-39.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.47%
EBIT Next 3Y41.8%
EBIT Next 5Y29.98%
FCF growth 1Y29.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.7%
OCF growth 3YN/A
OCF growth 5YN/A
NATERA INC / NTRA Fundamental Analysis FAQ
What is the ChartMill fundamental rating of NATERA INC (NTRA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to NTRA.
What is the valuation status of NATERA INC (NTRA) stock?
ChartMill assigns a valuation rating of 2 / 10 to NATERA INC (NTRA). This can be considered as Overvalued.
How profitable is NATERA INC (NTRA) stock?
NATERA INC (NTRA) has a profitability rating of 3 / 10.
How financially healthy is NATERA INC?
The financial health rating of NATERA INC (NTRA) is 7 / 10.
What is the expected EPS growth for NATERA INC (NTRA) stock?
The Earnings per Share (EPS) of NATERA INC (NTRA) is expected to decline by -25.06% in the next year.